Cargando...
Chemotherapy-Refractory Diffuse Large B-Cell Lymphoma and Indolent B-Cell Malignancies Can Be Effectively Treated With Autologous T Cells Expressing an Anti-CD19 Chimeric Antigen Receptor
PURPOSE: T cells can be genetically modified to express an anti-CD19 chimeric antigen receptor (CAR). We assessed the safety and efficacy of administering autologous anti-CD19 CAR T cells to patients with advanced CD19(+) B-cell malignancies. PATIENTS AND METHODS: We treated 15 patients with advance...
Guardado en:
Publicado en: | J Clin Oncol |
---|---|
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , |
Formato: | Artigo |
Lenguaje: | Inglês |
Publicado: |
American Society of Clinical Oncology
2015
|
Materias: | |
Acceso en línea: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4322257/ https://ncbi.nlm.nih.gov/pubmed/25154820 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2014.56.2025 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|